How IIT-K’s DKC1 Discovery Can Reshape Cancer Care

Furthermore, researchers at IIT Kanpur made a breakthrough that could reshape colorectal cancer treatment. Specifically, the team identified a protein that enables cancer cells to withstand chemotherapy. Consequently, this discovery offers fresh hope for patients who struggle with drug resistance, an area that remains a primary focus in oncology clinical practice.

The Role of DKC1 in Colorectal Cancer Treatment Resistance

Until now, scientists mainly recognized DKC1 for supporting basic cellular functions like growth and ageing. However, this joint research effort revealed a more dangerous role. Indeed, high levels of DKC1 allow cancer cells to bypass the body’s natural self-destruction machinery. Normally, unhealthy cells destroy themselves through apoptosis. Nevertheless, DKC1 actively interferes with this protective process, which helps tumours survive and grow much faster. In addition, the protein alters how cancer cells change fat production mechanisms. This lipid dysregulation further drives the progression of the disease.

Overcoming Chemotherapy Resistance

To address this challenge, researchers performed detailed laboratory experiments. Remarkably, targeting or reducing DKC1 levels slowed down tumour growth significantly. Moreover, this intervention made the cancer cells far more sensitive to standard chemotherapy drugs. Prof Bushra Ateeq spearheads the department of biological sciences and bioengineering at IIT-K. She explained that blocking signalling pathways linked to DKC1 and fat production weakened cancer progression. Therefore, therapeutic interventions targeting this specific axis could pave the way for redesigned treatment strategies. Specifically, these strategies will benefit patients who do not respond to conventional chemotherapy.

Clinical Implications and Collaborative Efforts

Furthermore, findings from human patients showed a clear correlation with laboratory results. Clinically, individuals with higher DKC1 levels experienced advanced disease states and poorer survival rates. Consequently, DKC1 could eventually serve as an invaluable biomarker. This biomarker will help clinicians identify patients who require targeted therapies rather than routine treatments. This collaborative study involved researchers from the Tata Memorial Centre in Mumbai and King George’s Medical University in Lucknow. Additionally, specialists from the Henry Ford Health System in the USA participated in this study. The prestigious journal Nature Communications published these groundbreaking findings.

Frequently Asked Questions

Q1: What is DKC1, and how does it affect colorectal cancer treatment?

DKC1 is a protein that is traditionally linked to cellular growth and ageing. However, researchers discovered that high levels of DKC1 help cancer cells bypass self-destruction, thereby promoting resistance to standard chemotherapy treatments.

Q2: How does targeting DKC1 help in managing colorectal cancer?

Targeting DKC1 levels in laboratory experiments has been shown to slow down tumour growth. In addition, blocking its signaling pathway makes cancer cells more sensitive to conventional chemotherapy, offering a new avenue for targeted oncology therapies.

References

1. IIT-K researchers identify protein enabling colorectal cells withstandchemotherapy – ETHealthworld
2. Khan, U. K., Goel, A., Nigam, S., et al. (2026). DKC1 promotes colorectal cancer progression and therapy resistance by dysregulating sphingolipid biosynthesis. Nature Communications, 17(1), 4406.

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.